ERBB2 and breast cancer: In addition, the combination of entinostat with nivolumab and ipilimumab in patients with advanced HER2 negative breast cancers demonstrated altered myeloid-derived suppressor cell (MDSC) signaling pathway and increased immune infiltration (27).